JP2010518128A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518128A5
JP2010518128A5 JP2009549348A JP2009549348A JP2010518128A5 JP 2010518128 A5 JP2010518128 A5 JP 2010518128A5 JP 2009549348 A JP2009549348 A JP 2009549348A JP 2009549348 A JP2009549348 A JP 2009549348A JP 2010518128 A5 JP2010518128 A5 JP 2010518128A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
independently
optionally substituted
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009549348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010518128A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/000293 external-priority patent/WO2008098368A1/en
Publication of JP2010518128A publication Critical patent/JP2010518128A/ja
Publication of JP2010518128A5 publication Critical patent/JP2010518128A5/ja
Pending legal-status Critical Current

Links

JP2009549348A 2007-02-16 2008-02-15 C型肝炎ns3プロテアーゼのインヒビター Pending JP2010518128A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89030407P 2007-02-16 2007-02-16
PCT/CA2008/000293 WO2008098368A1 (en) 2007-02-16 2008-02-15 Inhibitors of hepatitis c ns3 protease

Publications (2)

Publication Number Publication Date
JP2010518128A JP2010518128A (ja) 2010-05-27
JP2010518128A5 true JP2010518128A5 (enExample) 2011-04-07

Family

ID=39689592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009549348A Pending JP2010518128A (ja) 2007-02-16 2008-02-15 C型肝炎ns3プロテアーゼのインヒビター

Country Status (5)

Country Link
US (1) US20100087382A1 (enExample)
EP (1) EP2125870A4 (enExample)
JP (1) JP2010518128A (enExample)
CA (1) CA2676297A1 (enExample)
WO (1) WO2008098368A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2008137779A2 (en) * 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CA2686546A1 (en) * 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
WO2009142842A2 (en) * 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
WO2010045266A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
AU2010249080A1 (en) 2009-05-12 2012-01-12 Merck Sharp & Dohme Corp. Fused tricyclic aryl compounds useful for the treatment of viral diseases
EP2435421A1 (en) 2009-05-29 2012-04-04 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
JP2012528195A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション C型肝炎などの疾患を処置するための3つの結合アリール部分で構成された抗菌性化合物
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
CN105001302A (zh) * 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
WO2011066241A1 (en) * 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
MA34147B1 (fr) * 2010-03-09 2013-04-03 Merck Sharp & Dohme Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
CA2936749C (en) * 2010-06-11 2019-07-09 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 c형 간염 세린 프로테아제 억제제
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN107847609A (zh) 2015-03-13 2018-03-27 恩多塞特公司 用于治疗疾病的缀合物
CN115806518A (zh) * 2022-12-29 2023-03-17 南京安伦化工科技有限公司 一种N-Boc-4-氧代-脯氨酸甲酯的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4914348B2 (ja) * 2004-06-28 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング C型肝炎インヒビターペプチド類似体
US7592336B2 (en) * 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) * 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Similar Documents

Publication Publication Date Title
JP2012526728A5 (enExample)
JP2013508279A5 (enExample)
JP2013523765A5 (enExample)
JP2011523952A5 (enExample)
JP2017523169A5 (enExample)
JP2009504772A5 (enExample)
JP2015500843A5 (enExample)
JP2013537905A5 (enExample)
JP2016006118A5 (enExample)
JP2012524055A5 (enExample)
JP2017510610A5 (enExample)
JP2010535785A5 (enExample)
JP2011520815A5 (enExample)
JP2013532652A5 (enExample)
JP2018135343A5 (enExample)
JP2012092103A5 (enExample)
JP2015517555A5 (enExample)
JP2016518437A5 (enExample)
JP2013503846A5 (enExample)
JP2013545818A5 (enExample)
JP2013538230A5 (enExample)
JP2014513954A5 (enExample)
JP2013545817A5 (enExample)
JP2013537203A5 (enExample)
JP2013544860A5 (enExample)